Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achondroplasia D000130 1 associated lipids
Acinetobacter Infections D000151 4 associated lipids
Acne Vulgaris D000152 35 associated lipids
Acquired Immunodeficiency Syndrome D000163 12 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Agammaglobulinemia D000361 4 associated lipids
Airway Obstruction D000402 13 associated lipids
Amebiasis D000562 2 associated lipids
Anaphylaxis D000707 35 associated lipids
Anaplasmataceae Infections D000711 3 associated lipids
Angina, Unstable D000789 14 associated lipids
Aphasia, Broca D001039 1 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bartonella Infections D001474 3 associated lipids
Birth Weight D001724 23 associated lipids
Bites, Human D001734 2 associated lipids
Blister D001768 16 associated lipids
Body Weight D001835 333 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burns D002056 34 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cat Diseases D002371 12 associated lipids
Cat-Scratch Disease D002372 4 associated lipids
Uterine Cervicitis D002575 3 associated lipids
Chancroid D002602 4 associated lipids
Chlamydia Infections D002690 7 associated lipids
Chlamydiaceae Infections D002694 2 associated lipids
Chronic Disease D002908 7 associated lipids
Ciliary Motility Disorders D002925 2 associated lipids
Colitis D003092 69 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Conjunctivitis, Inclusion D003235 4 associated lipids
Corneal Opacity D003318 3 associated lipids
Coronary Disease D003327 70 associated lipids
Corynebacterium Infections D003354 7 associated lipids
Crohn Disease D003424 12 associated lipids
Cross Infection D003428 9 associated lipids
Cryptosporidiosis D003457 3 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cytomegalovirus Infections D003586 7 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Euba B et al. Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection. 2015 Antimicrob. Agents Chemother. pmid:25712355
Liu P et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. 2007 Antimicrob. Agents Chemother. pmid:17060516
Strickman D et al. In vitro effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus. 1995 Antimicrob. Agents Chemother. pmid:8585717
Batt SL et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. 2003 Antimicrob. Agents Chemother. pmid:12936971
Henry DC et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. 2003 Antimicrob. Agents Chemother. pmid:12936972
Kohlhoff SA et al. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. 2014 Antimicrob. Agents Chemother. pmid:25288086
Conte JE et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. 1996 Antimicrob. Agents Chemother. pmid:8807050
Nash KA and Inderlied CB Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. 1996 Antimicrob. Agents Chemother. pmid:8807078
Phimda K et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. 2007 Antimicrob. Agents Chemother. pmid:17638700
Bosnar M et al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. 2005 Antimicrob. Agents Chemother. pmid:15917536
Michot JM et al. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. 2004 Antimicrob. Agents Chemother. pmid:15215125
Hoberman A and Paradise JL Study design questions in treatment of children with acute otitis media. 2004 Antimicrob. Agents Chemother. pmid:15215151
Singh S et al. Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. 2014 Antimicrob. Agents Chemother. pmid:24890593
Johnson MM et al. Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. 1999 Antimicrob. Agents Chemother. pmid:10428903
Credito KL et al. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. 1999 Antimicrob. Agents Chemother. pmid:10428930
Unemo M et al. First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? 2014 Antimicrob. Agents Chemother. pmid:24189248
Li H et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. 2014 Antimicrob. Agents Chemother. pmid:24189261
Navarro G et al. Image-based 384-well high-throughput screening method for the discovery of skyllamycins A to C as biofilm inhibitors and inducers of biofilm detachment in Pseudomonas aeruginosa. 2014 Antimicrob. Agents Chemother. pmid:24295976
Ríos AM et al. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. 2005 Antimicrob. Agents Chemother. pmid:16127085
Binet R et al. Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs. 2010 Antimicrob. Agents Chemother. pmid:20065052
Blais J et al. Inhibition of Toxoplasma gondii protein synthesis by azithromycin. 1993 Antimicrob. Agents Chemother. pmid:8215287
Dever LL et al. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. 1993 Antimicrob. Agents Chemother. pmid:8215288
Edelstein PH and Edelstein MA In vitro activity of azithromycin against clinical isolates of Legionella species. 1991 Antimicrob. Agents Chemother. pmid:1849708
Ohara T et al. Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. 2002 Antimicrob. Agents Chemother. pmid:12384353
Berry V et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. 1998 Antimicrob. Agents Chemother. pmid:9835514
Biedenbach DJ et al. Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. 2010 Antimicrob. Agents Chemother. pmid:20625152
Piesman J et al. Efficacy of an experimental azithromycin cream for prophylaxis of tick-transmitted lyme disease spirochete infection in a murine model. 2014 Antimicrob. Agents Chemother. pmid:24165183
Bastian S et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. 2011 Antimicrob. Agents Chemother. pmid:21135185
Chisholm SA et al. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. 2010 Antimicrob. Agents Chemother. pmid:20585125
Fischer JH et al. Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. 2012 Antimicrob. Agents Chemother. pmid:22106226
Jepras RI et al. Rapid assessment of antibiotic effects on Escherichia coli by bis-(1,3-dibutylbarbituric acid) trimethine oxonol and flow cytometry. 1997 Antimicrob. Agents Chemother. pmid:9303401
Deshpande D et al. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. 2016 Antimicrob. Agents Chemother. pmid:26810646
Azoulay-Dupuis E et al. Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. 1991 Antimicrob. Agents Chemother. pmid:1656849
Amacher DE et al. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. 1991 Antimicrob. Agents Chemother. pmid:1656856
Fass RJ Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. 1993 Antimicrob. Agents Chemother. pmid:8257127
Gunell M et al. In vitro activity of azithromycin against nontyphoidal Salmonella enterica. 2010 Antimicrob. Agents Chemother. pmid:20498312
Bermudez LE et al. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. 1998 Antimicrob. Agents Chemother. pmid:9449283
Roblin PM and Hammerschlag MR Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. 1998 Antimicrob. Agents Chemother. pmid:9449287
Pene Dumitrescu T et al. Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. 2013 Antimicrob. Agents Chemother. pmid:23629714
Amsden GW et al. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. 1999 Antimicrob. Agents Chemother. pmid:9869584
Gelber RH et al. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. 1991 Antimicrob. Agents Chemother. pmid:1648889
Pérez-Martínez I and Haas D Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa. 2011 Antimicrob. Agents Chemother. pmid:21537014
Salman S et al. Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling. 2017 Antimicrob. Agents Chemother. pmid:28242669
Goswick SM and Brenner GM Activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. 2003 Antimicrob. Agents Chemother. pmid:12543653
Hoffman HL et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. 2003 Antimicrob. Agents Chemother. pmid:12543686
Breitschwerdt EB et al. Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs. 1999 Antimicrob. Agents Chemother. pmid:10103185
Lai PC and Walters JD Azithromycin kills invasive Aggregatibacter actinomycetemcomitans in gingival epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23274657
Sjölund Karlsson M et al. Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States. 2013 Antimicrob. Agents Chemother. pmid:23274665
Hafner R et al. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. 2001 Antimicrob. Agents Chemother. pmid:11302832
Donati M et al. In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. 2010 Antimicrob. Agents Chemother. pmid:20855744